We are live on
!
Find out more
MoonLake Immunotherapeutics
MLTX
MLTX
130 hedge funds and large institutions have $743M invested in MoonLake Immunotherapeutics in 2025 Q4 according to their latest regulatory filings, with 47 funds opening new positions, 55 increasing their positions, 23 reducing their positions, and 47 closing their positions.
New
Increased
Maintained
Reduced
Closed
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
176% more call options, than puts
Call options by funds: $37.5M | Put options by funds: $13.6M
175% more capital invested
Capital invested by funds: $270M → $743M (+$473M)
139% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 23
29.2% more ownership
Funds ownership: 59.27% → 88.47% (+29%)
0% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 47
3% less funds holding
Funds holding: 134 → 130 (-4)
Holders
130
Holders Change
-4
Holders Change %
-2.99%
% of All Funds
1.58%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.04%
New
47
Increased
55
Reduced
23
Closed
47
Calls
$37.5M
Puts
$13.6M
Net Calls
+$23.9M
Net Calls Change
+$5.17M
Top Buyers
Top Sellers
| 1 |
ACA
Avoro Capital Advisors
New York
|
-$14.3M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$10.8M |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$7.59M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.73M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$3.12M |